Avedro submits VibeX/KXL System NDA with FDA to treat keratoconus, corneal ectasia

Avedro, Inc. announced today that the Company submitted a New Drug Application (NDA) to the United States Food and Drug Administration (FDA) for its VibeX (riboflavin ophthalmic solution) /KXL System for the treatment of keratoconus and corneal ectasia following refractive surgery.

Full Story →